Catherine Kegakilwe Koofhethile, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Proviruses | 4 | 2023 | 313 | 1.750 |
Why?
|
HIV-1 | 8 | 2024 | 6850 | 1.000 |
Why?
|
HIV Infections | 12 | 2024 | 17159 | 0.730 |
Why?
|
HIV Seropositivity | 2 | 2023 | 955 | 0.720 |
Why?
|
Viremia | 2 | 2024 | 708 | 0.620 |
Why?
|
Virus Activation | 1 | 2019 | 319 | 0.590 |
Why?
|
DNA, Viral | 2 | 2022 | 2195 | 0.540 |
Why?
|
Viral Load | 6 | 2024 | 3323 | 0.530 |
Why?
|
Antiretroviral Therapy, Highly Active | 3 | 2024 | 1894 | 0.480 |
Why?
|
T-Lymphocytes, Cytotoxic | 2 | 2016 | 1765 | 0.340 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2016 | 1354 | 0.340 |
Why?
|
CD8-Positive T-Lymphocytes | 4 | 2016 | 4554 | 0.310 |
Why?
|
Botswana | 4 | 2024 | 1042 | 0.280 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2023 | 4355 | 0.250 |
Why?
|
Leukocytes, Mononuclear | 2 | 2023 | 1828 | 0.250 |
Why?
|
Immunodominant Epitopes | 2 | 2015 | 241 | 0.230 |
Why?
|
HIV-2 | 1 | 2023 | 156 | 0.210 |
Why?
|
Mozambique | 1 | 2022 | 55 | 0.210 |
Why?
|
Oxazines | 1 | 2024 | 341 | 0.200 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2024 | 275 | 0.190 |
Why?
|
Epitopes, T-Lymphocyte | 3 | 2015 | 825 | 0.190 |
Why?
|
Pyridones | 1 | 2024 | 788 | 0.160 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 2 | 2015 | 206 | 0.140 |
Why?
|
HLA-B Antigens | 2 | 2015 | 331 | 0.130 |
Why?
|
Withholding Treatment | 1 | 2019 | 613 | 0.120 |
Why?
|
RNA | 1 | 2023 | 2721 | 0.110 |
Why?
|
Piperazines | 1 | 2024 | 2520 | 0.110 |
Why?
|
Immune Evasion | 1 | 2014 | 362 | 0.090 |
Why?
|
Receptors, Antigen, T-Cell | 2 | 2015 | 2536 | 0.080 |
Why?
|
Virus Replication | 1 | 2016 | 2431 | 0.080 |
Why?
|
HIV | 1 | 2014 | 1579 | 0.070 |
Why?
|
HLA Antigens | 1 | 2010 | 1369 | 0.060 |
Why?
|
Tropism | 1 | 2023 | 43 | 0.050 |
Why?
|
Humans | 12 | 2024 | 760261 | 0.050 |
Why?
|
Epitopes | 2 | 2023 | 2506 | 0.050 |
Why?
|
Viral Tropism | 1 | 2023 | 102 | 0.050 |
Why?
|
Epitope Mapping | 2 | 2015 | 297 | 0.050 |
Why?
|
HIV Integrase Inhibitors | 1 | 2024 | 165 | 0.050 |
Why?
|
Adolescent | 2 | 2020 | 87747 | 0.050 |
Why?
|
Adult | 6 | 2024 | 219847 | 0.050 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 1 | 2023 | 368 | 0.050 |
Why?
|
Infant | 1 | 2022 | 36030 | 0.040 |
Why?
|
Longitudinal Studies | 1 | 2016 | 14482 | 0.040 |
Why?
|
Infant, Newborn | 1 | 2019 | 26168 | 0.040 |
Why?
|
Follow-Up Studies | 1 | 2019 | 39254 | 0.040 |
Why?
|
Treatment Failure | 1 | 2024 | 2646 | 0.040 |
Why?
|
Time Factors | 1 | 2019 | 40133 | 0.040 |
Why?
|
HIV Antibodies | 1 | 2023 | 1300 | 0.030 |
Why?
|
Software | 1 | 2010 | 4420 | 0.030 |
Why?
|
Antibody Affinity | 1 | 2015 | 245 | 0.030 |
Why?
|
Anti-HIV Agents | 2 | 2024 | 4492 | 0.030 |
Why?
|
Antibodies, Neutralizing | 1 | 2023 | 1933 | 0.030 |
Why?
|
Anti-Retroviral Agents | 1 | 2023 | 1780 | 0.030 |
Why?
|
DNA, Complementary | 1 | 2015 | 1993 | 0.020 |
Why?
|
Amino Acid Sequence | 2 | 2015 | 13456 | 0.020 |
Why?
|
Enzyme-Linked Immunospot Assay | 1 | 2010 | 123 | 0.020 |
Why?
|
Selection, Genetic | 1 | 2014 | 872 | 0.020 |
Why?
|
Databases, Protein | 1 | 2010 | 388 | 0.020 |
Why?
|
Male | 3 | 2024 | 359413 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2014 | 2563 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2015 | 4717 | 0.010 |
Why?
|
Base Sequence | 1 | 2015 | 12447 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2014 | 5498 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2010 | 3160 | 0.010 |
Why?
|
Cohort Studies | 2 | 2014 | 41317 | 0.010 |
Why?
|
Genotype | 1 | 2014 | 12959 | 0.010 |
Why?
|
Peptides | 1 | 2010 | 4358 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2010 | 17628 | 0.010 |
Why?
|
Cell Line | 1 | 2010 | 15626 | 0.010 |
Why?
|
Middle Aged | 2 | 2024 | 220175 | 0.010 |
Why?
|
Female | 3 | 2024 | 391011 | 0.010 |
Why?
|